18 completed, 7 active not recruiting, 3 terminated, 3 unknown. 20 Phase 2, 15 Phase 1, 3 Phase 3.
Follow guadecitabine: new trials by email Literature Review of guadecitabine trials Research Report on guadecitabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma Belinostat, Biopsy Procedure, Biospecimen Collection - Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2020-09-08 | 2026-11-13 |
| A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 Ipilimumab plus nivolumab plus guadecitabine, Ipilimumab plus nivolumab - Melanoma, Non Small Cell Lung Cancer | Phase 2 | Unknown | Italian Network for Tumor Biotherapy Foundation | 184 | 2020-03-01 | 2020-01-31 |
| Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer Guadecitabine, Nivolumab - Colorectal Adenocarcinoma, CpG Island Methylator Phenotype | Phase 1 / Phase 2 | Withdrawn | University of Southern California | 2020-01-30 | 2021-04-05 | |
| Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer Guadecitabine, Carboplatin - Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer | Phase 2 | Completed | Shadia Jalal, MD | 24 | 2019-06-06 | 2023-12-20 |
| SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation Guadecitabine - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Unknown | Groupe Francophone des Myelodysplasies | 40 | 2018-11-01 | 2018-11-15 |
| Guadecitabine Extension Study Guadecitabine - Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome | Phase 2 | Terminated | Astex Pharmaceuticals, Inc. | 35 | 2018-07-18 | 2024-08-27 |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Durvalumab, Guadecitabine - Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type | Phase 1 | Active not recruiting | University of Southern California | 55 | 2018-02-07 | 2026-06-01 |
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer Guadecitabine, Durvalumab - Advanced Kidney Cancer, Kidney Cancer | Phase 1 / Phase 2 | Active not recruiting | Ajjai Alva, MD | 57 | 2017-12-19 | 2022-02-17 |
| SGI-110 Plus Durvalumab/Tremelimumab in SCLC Durvalumab, Tremelimumab, SGI-110 - Extensive-stage Small Cell Lung Cancer | Phase 1 | Completed | Catherine Shu | 2 | 2017-12-15 | 2018-12-10 |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma Atezolizumab, Guadecitabine - Urothelial Carcinoma | Phase 2 | Active not recruiting | Fox Chase Cancer Center | 21 | 2017-11-27 | 2021-11-04 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-11-08 | 2026-10-20 |
| A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer SGI-110 (guadecitabine) - Paraganglioma, Gastrointestinal Stromal Tumors | Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-08-16 | 2026-02-18 |
| Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. Pembrolizumab, Guadecitabine, Mocetinostat - Lung Cancer | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 28 | 2017-08-04 | 2026-08-05 |
| Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia guadecitabine, Treatment Choice (TC) - Acute Myeloid Leukemia | Phase 3 | Completed | Astex Pharmaceuticals, Inc. | 302 | 2017-03-16 | 2024-08-28 |
| Combination Study of Guadecitabine/ASTX727 and Pembrolizumab Guadecitabine, Pembrolizumab, ASTX727 - Non Small Cell Lung Cancer | Phase 1 | Active not recruiting | Royal Marsden NHS Foundation Trust | 60 | 2017-01-26 | 2026-05-12 |
| Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Guadecitabine, Treatment Choice - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 3 | Completed | Astex Pharmaceuticals, Inc. | 417 | 2017-01-13 | 2024-08-27 |
| Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Guadecitabine, Laboratory Biomarker Analysis, Pembrolizumab - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 45 | 2016-11-11 | 2024-02-20 |
| Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Atezolizumab, Guadecitabine - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 33 | 2016-11-02 | 2026-07-07 |
| A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) Atezolizumab, Guadecitabine - Acute Myeloid Leukemia | Phase 1 | Completed | Hoffmann-La Roche | 40 | 2016-10-31 | 2020-03-13 |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant Donor Lymphocytes, Guadecitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 55 | 2016-06-22 | 2025-11-06 |
Showing 20 of 32. Sign in to see all of them.
Leukemia, Myeloid, Acute (7) · Myelodysplastic Syndromes (4) · Leukemia, Myelomonocytic, Chronic (3) · Ovarian Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Fallopian Tube Neoplasms (2) · Kidney Neoplasms (2) · Melanoma (2) · Small Cell Lung Carcinoma (2) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colonic Diseases (1)
Astex Pharmaceuticals, Inc. (7) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · University of Southern California (3) · Italian Network for Tumor Biotherapy Foundation (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Ajjai Alva, MD (1) · Catherine Shu (1) · Fox Chase Cancer Center (1) · Groupe Francophone des Myelodysplasies (1) · Hoffmann-La Roche (1) · Memorial Sloan Kettering Cancer Center (1) · Nasser Hanna (1) · Northwestern University (1) · Otsuka Pharmaceutical Co., Ltd. (1)
United States (27) · Canada (7) · Italy (6) · United Kingdom (6) · Japan (5) · Denmark (4) · France (4) · South Korea (4) · Spain (4) · Belgium (3) · Germany (3) · Poland (3) · Sweden (3) · Austria (2) · Czechia (2)
Ajjai Alva, M.D. (1) · Anna Maria Di Giacomo, MD (1) · Anna Maria Di Giacomo, PhD,MD (1) · Anthony El-Khoueiry, MD (1) · Betul Oran, MD (1) · Casey O'Connell (1) · Catherine Shu, MD (1) · Daniela Matei, MD (1) · Guillermo Garcia-Manero (1) · Hagop M Kantarjian (1) · Harold N Keer, MD, PhD (1) · Heinz-Josef Lenz, MD (1) · John W Glod, M.D. (1) · Junji Ikeda (1)
PMID 16882708, PMID 26296954, PMID 28445481, PMID 31060979, PMID 31331399, PMID 31831561, PMID 33289590, PMID 33531075, PMID 34552007, PMID 35671108, PMID 35717027, PMID 36302175, PMID 36934257, PMID 37276510, PMID 37739939, PMID 38231126, PMID 38302476, PMID 38312102, PMID 40454402
P30CA014089 (3), 2015 (1), P30CA016056 (1), P30CA060553 (1), UM1CA186686 (1)